<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;ff=20240710141400&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;ff=20240710141400&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 10 Jul 2024 18:14:00 +0000</lastbuilddate>
<pubDate>Wed, 10 Jul 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Women's Representation in Interventional Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38985493/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240710141400&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jul 10. doi: 10.1001/jamacardio.2024.1724. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38985493/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240710141400&v=2.18.0.post9+e462414">38985493</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.1724>10.1001/jamacardio.2024.1724</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38985493</guid>
<pubDate>Wed, 10 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Sarah K Gualano</dc:creator>
<dc:creator>James Henderson</dc:creator>
<dc:creator>Stacy Menees</dc:creator>
<dc:creator>Ashwini Kerkar</dc:creator>
<dc:creator>Erika Parisi</dc:creator>
<dc:creator>Eve A Kerr</dc:creator>
<dc:date>2024-07-10</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Women's Representation in Interventional Cardiology</dc:title>
<dc:identifier>pmid:38985493</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.1724</dc:identifier>
</item>
<item>
<title>Indigenous Representation and Belonging in Cardiology-Reply</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38985491/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240710141400&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jul 10. doi: 10.1001/jamacardio.2024.1709. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38985491/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240710141400&v=2.18.0.post9+e462414">38985491</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.1709>10.1001/jamacardio.2024.1709</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38985491</guid>
<pubDate>Wed, 10 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Sarah C Snow</dc:creator>
<dc:creator>Brooke Alhanti</dc:creator>
<dc:creator>Pamela S Douglas</dc:creator>
<dc:date>2024-07-10</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Indigenous Representation and Belonging in Cardiology-Reply</dc:title>
<dc:identifier>pmid:38985491</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.1709</dc:identifier>
</item>
<item>
<title>Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38985488/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240710141400&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this secondary analysis of the ADAPTABLE trial, there were no significant sex-specific differences in the effectiveness and safety of 2 aspirin doses for secondary prevention of ASCVD events.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jul 10. doi: 10.1001/jamacardio.2024.1712. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality in the US. Although aspirin is recommended for secondary prevention of ASCVD, there was no difference in safety and effectiveness of aspirin dosed daily at 81 mg or 325 mg in the ADAPTABLE (Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness) randomized clinical trial. However, it is unknown whether differences by sex exist in the safety and effectiveness of the different aspirin doses.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate sex-specific differences in the safety and effectiveness of 2 aspirin doses in the ADAPTAPLE trial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The ADAPTABLE study was an open-label, pragmatic, randomized clinical trial that randomly assigned participants with chronic, stable ASCVD to 81 mg vs 325 mg of aspirin daily. Using Cox proportional-hazard models, male and female participants were compared for outcomes. In addition, it was assessed whether sex was an effect modifier in the association between aspirin dose and outcomes. The ADAPTABLE trial was conducted at 40 medical centers and 1 health plan. Eligible patients were 18 years and older and had established ASCVD. Study data were analyzed from December 2021 to March 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Patients received 81 mg or 325 mg of aspirin daily for the secondary prevention of ASCVD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary effectiveness outcomes included all-cause death and hospitalization for myocardial infarction (MI) or stroke. The primary safety outcome was hospitalization for major bleeding requiring transfusion.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 15 076 patients (median [IQR] age, 67.6 [60.7-73.6] years; 10 352 male [68.7%]) were followed up for a median (IQR) of 26.2 (19.0-34.9) months. Overall, 4724 (31.3%) were female, and 2307 of the female participants (48.8%) received aspirin 81 mg. Compared with males, female participants were younger (median [IQR] age, 66.3 [59.4-72.6] years vs 68.2 (61.4-73.9) years, less likely to self-report White race (3426 [72.5%] vs 8564 [82.7%]), more likely to smoke (564 [12.9%] vs 818 [8.4%]), and more likely to have a history of peripheral arterial disease (1179 [25.7%] vs 2314 [23.0%]). The primary effectiveness outcome of all-cause death and hospitalization for MI or stroke occurred in 379 female participants (8.1%) and 780 male participants (7.1%). There was no significant interaction by sex for the primary effectiveness end point between the 2 aspirin doses (female adjusted hazard ratio [aHR], 1.01; 95% CI, 0.82-1.26 and male aHR, 1.06; 95% CI, 0.91-1.23; P interaction term for sex = .74). During the trial, female participants had fewer revascularization procedures (237 [5.0%] vs 680 [6.6%]; aHR, 0.79; 95% CI, 0.68-0.92; P = .002) but had a higher risk of hospitalization for stroke (aHR, 1.72; 95% CI, 1.27-2.33; P &lt; .001). Among female participants, there was a slightly higher rate of bleeding in the 81-mg aspirin cohort compared with the 325-mg cohort (20 [0.83%] vs 13 [0.52%]; aHR, 2.21; 95% CI, 1.04-4.70; P interaction term for sex = .07). There were no significant differences between female and male participants regarding aspirin dose adherence.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this secondary analysis of the ADAPTABLE trial, there were no significant sex-specific differences in the effectiveness and safety of 2 aspirin doses for secondary prevention of ASCVD events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02697916.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38985488/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240710141400&v=2.18.0.post9+e462414">38985488</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.1712>10.1001/jamacardio.2024.1712</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38985488</guid>
<pubDate>Wed, 10 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Catherine P Benziger</dc:creator>
<dc:creator>Amanda Stebbins</dc:creator>
<dc:creator>Lisa M Wruck</dc:creator>
<dc:creator>Mark B Effron</dc:creator>
<dc:creator>Guillaume Marquis-Gravel</dc:creator>
<dc:creator>Peter M Farrehi</dc:creator>
<dc:creator>Saket Girotra</dc:creator>
<dc:creator>Kamal Gupta</dc:creator>
<dc:creator>Sunil Kripalani</dc:creator>
<dc:creator>Daniel Munoz</dc:creator>
<dc:creator>Tamar S Polonsky</dc:creator>
<dc:creator>Amber Sharlow</dc:creator>
<dc:creator>Jeffrey Whittle</dc:creator>
<dc:creator>Robert A Harrington</dc:creator>
<dc:creator>Russell L Rothman</dc:creator>
<dc:creator>Adrian F Hernandez</dc:creator>
<dc:creator>W Schuyler Jones</dc:creator>
<dc:date>2024-07-10</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:38985488</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.1712</dc:identifier>
</item>
<item>
<title>Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation: Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38985461/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240710141400&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this post hoc analysis of the ENGAGE AF-TIMI 48 randomized clinical trial, in patients 80 years and older with atrial fibrillation, major bleeding events were lower in patients randomized to receive edoxaban, 30 mg per day, compared with either edoxaban, 60 mg per day (in patients without dose-reduction criteria), or warfarin (irrespective of dose-reduction status), without an offsetting increase in ischemic events. These data support the concept that lower-dose...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jul 10. doi: 10.1001/jamacardio.2024.1793. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: In older patients with atrial fibrillation who take anticoagulants for stroke prevention, bleeding is increased compared with younger patients, thus, clinicians frequently prescribe lower than recommended doses in older patients despite limited randomized data.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate ischemic and bleeding outcomes in patients 80 years and older with atrial fibrillation receiving edoxaban, 60 mg vs 30 mg, and edoxaban, 30 mg vs warfarin.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The ENGAGE AF-TIMI 48 trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) was a parallel-design, double-blind, global clinical trial that randomized patients with atrial fibrillation to either one of 2 edoxaban dosing regimens or warfarin. This secondary analysis focused on patients 80 years or older without dose-reduction criteria receiving edoxaban, 60 mg vs 30 mg, as well as patients with or without dose-reduction criteria receiving edoxaban, 30 mg, vs warfarin. Study data were analyzed between October 2022 and December 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Oral edoxaban, 30 mg once daily; edoxaban, 60 mg once daily; or warfarin.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Primary net clinical outcome of death, stroke or systemic embolism, and major bleeding and each individual component.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The current analysis included 2966 patients 80 years and older (mean [SD] age, 83 [2.7] years; 1671 male [56%]). Among 1138 patients 80 years and older without dose-reduction criteria, those receiving edoxaban, 60 mg vs 30 mg, had more major bleeding events (hazard ratio [HR], 1.57; 95% CI, 1.04-2.38; P = .03), particularly gastrointestinal hemorrhage (HR, 2.24; 95% CI, 1.29-3.90; P = .004), with no significant difference in efficacy end points. Findings were supported by analyses of endogenous factor Xa inhibition, a marker of anticoagulant effect, which was comparable between younger patients receiving edoxaban, 60 mg, and older patients receiving edoxaban, 30 mg. In 2406 patients 80 years and older with or without dose-reduction criteria, patients receiving edoxaban, 30 mg, vs warfarin had lower rates of the primary net clinical outcome (HR, 0.78; 95% CI, 0.68-0.91; P = .001), major bleeding (HR, 0.59; 95% CI, 0.45-0.77; P &lt; .001), and death (HR, 0.83; 95% CI, 0.70-1.00; P = .046), whereas rates of stroke or systemic embolism were comparable.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this post hoc analysis of the ENGAGE AF-TIMI 48 randomized clinical trial, in patients 80 years and older with atrial fibrillation, major bleeding events were lower in patients randomized to receive edoxaban, 30 mg per day, compared with either edoxaban, 60 mg per day (in patients without dose-reduction criteria), or warfarin (irrespective of dose-reduction status), without an offsetting increase in ischemic events. These data support the concept that lower-dose anticoagulants, such as edoxaban, 30 mg, may be considered in older patients with atrial fibrillation even in the absence of dose-reduction criteria.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00781391.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38985461/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240710141400&v=2.18.0.post9+e462414">38985461</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.1793>10.1001/jamacardio.2024.1793</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38985461</guid>
<pubDate>Wed, 10 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>André Zimerman</dc:creator>
<dc:creator>Eugene Braunwald</dc:creator>
<dc:creator>Jan Steffel</dc:creator>
<dc:creator>Nicolas M Van Mieghem</dc:creator>
<dc:creator>Michael G Palazzolo</dc:creator>
<dc:creator>Sabina A Murphy</dc:creator>
<dc:creator>Cathy Zi Li Chen</dc:creator>
<dc:creator>Martin Unverdorben</dc:creator>
<dc:creator>Christian T Ruff</dc:creator>
<dc:creator>Elliott M Antman</dc:creator>
<dc:creator>Robert P Giugliano</dc:creator>
<dc:date>2024-07-10</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation: Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:38985461</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.1793</dc:identifier>
</item>
<item>
<title>Indigenous Representation and Belonging in Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38985456/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240710141400&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jul 10. doi: 10.1001/jamacardio.2024.1706. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38985456/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240710141400&v=2.18.0.post9+e462414">38985456</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.1706>10.1001/jamacardio.2024.1706</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38985456</guid>
<pubDate>Wed, 10 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Jeffrey E Jones</dc:creator>
<dc:creator>Kekoa Taparra</dc:creator>
<dc:date>2024-07-10</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Indigenous Representation and Belonging in Cardiology</dc:title>
<dc:identifier>pmid:38985456</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.1706</dc:identifier>
</item>
<item>
<title>JAMA Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38985165/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240710141400&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jul 1;9(7):594. doi: 10.1001/jamacardio.2023.3667.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38985165/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240710141400&v=2.18.0.post9+e462414">38985165</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3667>10.1001/jamacardio.2023.3667</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38985165</guid>
<pubDate>Wed, 10 Jul 2024 06:00:00 -0400</pubDate>
<dc:date>2024-07-10</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>JAMA Cardiology</dc:title>
<dc:identifier>pmid:38985165</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3667</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: improved renal outcomes by semaglutide in patients with chronic kidney disease and type 2 diabetes in FLOW trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38985093/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240710141400&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 10:ehae429. doi: 10.1093/eurheartj/ehae429. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38985093/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240710141400&v=2.18.0.post9+e462414">38985093</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae429>10.1093/eurheartj/ehae429</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38985093</guid>
<pubDate>Wed, 10 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:creator>Massimo Volpe</dc:creator>
<dc:date>2024-07-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: improved renal outcomes by semaglutide in patients with chronic kidney disease and type 2 diabetes in FLOW trial</dc:title>
<dc:identifier>pmid:38985093</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae429</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: a 'thousand-mile' journey in obesity-related heart failure treatment begins with a few STEPs</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38985014/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240710141400&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 10:ehae427. doi: 10.1093/eurheartj/ehae427. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38985014/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240710141400&v=2.18.0.post9+e462414">38985014</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae427>10.1093/eurheartj/ehae427</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38985014</guid>
<pubDate>Wed, 10 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:creator>Massimo Volpe</dc:creator>
<dc:date>2024-07-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: a 'thousand-mile' journey in obesity-related heart failure treatment begins with a few STEPs</dc:title>
<dc:identifier>pmid:38985014</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae427</dc:identifier>
</item>
<item>
<title>Cardiogenic shock: do we need a paradigm shift?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38985011/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240710141400&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 10:ehae425. doi: 10.1093/eurheartj/ehae425. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38985011/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240710141400&v=2.18.0.post9+e462414">38985011</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae425>10.1093/eurheartj/ehae425</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38985011</guid>
<pubDate>Wed, 10 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Thomas F Lüscher</dc:creator>
<dc:creator>Holger Thiele</dc:creator>
<dc:date>2024-07-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardiogenic shock: do we need a paradigm shift?</dc:title>
<dc:identifier>pmid:38985011</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae425</dc:identifier>
</item>
<item>
<title>Genetics of hypertrophic cardiomyopathy: established and emerging implications for clinical practice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38984491/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240710141400&amp;v=2.18.0.post9+e462414
      <description>Pathogenic variation in genes encoding proteins of the cardiac sarcomere is responsible for 30%-40% of cases of hypertrophic cardiomyopathy. The main clinical utility of genetic testing is to provide diagnostic confirmation and facilitation of family screening. It also assists in the detection of aetiologies, which require distinct monitoring and treatment approaches. Other clinical applications, including the use of genetic information to inform risk prediction models, have been limited by the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 10:ehae421. doi: 10.1093/eurheartj/ehae421. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Pathogenic variation in genes encoding proteins of the cardiac sarcomere is responsible for 30%-40% of cases of hypertrophic cardiomyopathy. The main clinical utility of genetic testing is to provide diagnostic confirmation and facilitation of family screening. It also assists in the detection of aetiologies, which require distinct monitoring and treatment approaches. Other clinical applications, including the use of genetic information to inform risk prediction models, have been limited by the challenge of establishing robust genotype-phenotype correlations with actionable consequences, but new data on the interaction between rare and common genetic variation, as well as the emergence of therapies targeting disease-specific pathogenic mechanisms, herald a new era for genetic testing in routine practice.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38984491/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240710141400&v=2.18.0.post9+e462414">38984491</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae421>10.1093/eurheartj/ehae421</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38984491</guid>
<pubDate>Wed, 10 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Luis R Lopes</dc:creator>
<dc:creator>Carolyn Y Ho</dc:creator>
<dc:creator>Perry M Elliott</dc:creator>
<dc:date>2024-07-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Genetics of hypertrophic cardiomyopathy: established and emerging implications for clinical practice</dc:title>
<dc:identifier>pmid:38984491</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae421</dc:identifier>
</item>
<item>
<title>The ESC working group on pulmonary circulation and right ventricular function</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38984436/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240710141400&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 10:ehae297. doi: 10.1093/eurheartj/ehae297. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38984436/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240710141400&v=2.18.0.post9+e462414">38984436</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae297>10.1093/eurheartj/ehae297</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38984436</guid>
<pubDate>Wed, 10 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>George Giannakoulas</dc:creator>
<dc:creator>Frederikus A Klok</dc:creator>
<dc:date>2024-07-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The ESC working group on pulmonary circulation and right ventricular function</dc:title>
<dc:identifier>pmid:38984436</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae297</dc:identifier>
</item>
<item>
<title>Periprocedural Management and Multidisciplinary Care Pathways for Patients With Cardiac Implantable Electronic Devices: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38984417/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240710141400&amp;v=2.18.0.post9+e462414
      <description>The rapid technological advancements in cardiac implantable electronic devices such as pacemakers, implantable cardioverter defibrillators, and loop recorders, coupled with a rise in the number of patients with these devices, necessitate an updated clinical framework for periprocedural management. The introduction of leadless pacemakers, subcutaneous and extravascular defibrillators, and novel device communication protocols underscores the imperative for clinical updates. This scientific...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 10. doi: 10.1161/CIR.0000000000001264. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The rapid technological advancements in cardiac implantable electronic devices such as pacemakers, implantable cardioverter defibrillators, and loop recorders, coupled with a rise in the number of patients with these devices, necessitate an updated clinical framework for periprocedural management. The introduction of leadless pacemakers, subcutaneous and extravascular defibrillators, and novel device communication protocols underscores the imperative for clinical updates. This scientific statement provides an inclusive framework for the periprocedural management of patients with these devices, encompassing the planning phase, procedure, and subsequent care coordinated with the primary device managing clinic. Expert contributions from anesthesiologists, cardiac electrophysiologists, and cardiac nurses are consolidated to appraise current evidence, offer patient and health system management strategies, and highlight key areas for future research. The statement, pertinent to a wide range of health care professionals, underscores the importance of quality care pathways for patient safety, optimal device function, and minimization of hemodynamic disturbances or arrhythmias during procedures. Our primary objective is to deliver quality care to the expanding patient cohort with cardiac implanted electronic devices, offering direction in the era of evolving technologies and laying a foundation for sustained education and practice enhancement.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38984417/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240710141400&v=2.18.0.post9+e462414">38984417</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001264>10.1161/CIR.0000000000001264</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38984417</guid>
<pubDate>Wed, 10 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Elaine Y Wan</dc:creator>
<dc:creator>Albert J Rogers</dc:creator>
<dc:creator>Michael Lavelle</dc:creator>
<dc:creator>Mason Marcus</dc:creator>
<dc:creator>Sarah A Stone</dc:creator>
<dc:creator>Linda Ottoboni</dc:creator>
<dc:creator>Uma Srivatsa</dc:creator>
<dc:creator>Miguel A Leal</dc:creator>
<dc:creator>Andrea M Russo</dc:creator>
<dc:creator>Larry R Jackson</dc:creator>
<dc:creator>George H Crossley</dc:creator>
<dc:creator>American Heart Association Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Peripheral Vascular Disease</dc:creator>
<dc:date>2024-07-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Periprocedural Management and Multidisciplinary Care Pathways for Patients With Cardiac Implantable Electronic Devices: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:38984417</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001264</dc:identifier>
</item>
<item>
<title>Taking inspiration from birds to improve flow in prosthetic heart valves: an European Research Council granted project</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38984412/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240710141400&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 10:ehae330. doi: 10.1093/eurheartj/ehae330. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38984412/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240710141400&v=2.18.0.post9+e462414">38984412</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae330>10.1093/eurheartj/ehae330</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38984412</guid>
<pubDate>Wed, 10 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Yevgeniy Kreinin</dc:creator>
<dc:creator>Mark Epshtein</dc:creator>
<dc:creator>Gil Bolotin</dc:creator>
<dc:creator>Netanel Korin</dc:creator>
<dc:date>2024-07-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Taking inspiration from birds to improve flow in prosthetic heart valves: an European Research Council granted project</dc:title>
<dc:identifier>pmid:38984412</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae330</dc:identifier>
</item>
<item>
<title>Rising stars in cardiology: Srividya Velagapudi</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38984410/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240710141400&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 10:ehae328. doi: 10.1093/eurheartj/ehae328. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38984410/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240710141400&v=2.18.0.post9+e462414">38984410</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae328>10.1093/eurheartj/ehae328</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38984410</guid>
<pubDate>Wed, 10 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Judith Ozkan</dc:creator>
<dc:date>2024-07-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Rising stars in cardiology: Srividya Velagapudi</dc:title>
<dc:identifier>pmid:38984410</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae328</dc:identifier>
</item>
<item>
<title>Welcome to the exciting world of the right ventricle</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38984401/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240710141400&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 10:ehae377. doi: 10.1093/eurheartj/ehae377. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38984401/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240710141400&v=2.18.0.post9+e462414">38984401</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae377>10.1093/eurheartj/ehae377</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38984401</guid>
<pubDate>Wed, 10 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Julia Grapsa</dc:creator>
<dc:creator>Edoardo Zancanaro</dc:creator>
<dc:creator>Maurice Enriquez-Sarano</dc:creator>
<dc:date>2024-07-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Welcome to the exciting world of the right ventricle</dc:title>
<dc:identifier>pmid:38984401</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae377</dc:identifier>
</item>
<item>
<title>The ESC Working Group on e-Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38984398/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240710141400&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 10:ehae332. doi: 10.1093/eurheartj/ehae332. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38984398/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240710141400&v=2.18.0.post9+e462414">38984398</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae332>10.1093/eurheartj/ehae332</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38984398</guid>
<pubDate>Wed, 10 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Ruben Casado Arroyo</dc:creator>
<dc:creator>Magnus T Jensen</dc:creator>
<dc:creator>Polychronis Dilaveris</dc:creator>
<dc:creator>Emanuela T Locati</dc:creator>
<dc:creator>Raffaele De Lucia</dc:creator>
<dc:date>2024-07-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The ESC Working Group on e-Cardiology</dc:title>
<dc:identifier>pmid:38984398</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae332</dc:identifier>
</item>
<item>
<title>Time is relative, also when comparing transcatheter edge-to-edge repair to mitral valve surgery</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38984394/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240710141400&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 10:ehae383. doi: 10.1093/eurheartj/ehae383. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38984394/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240710141400&v=2.18.0.post9+e462414">38984394</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae383>10.1093/eurheartj/ehae383</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38984394</guid>
<pubDate>Wed, 10 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Ovidio A García-Villarreal</dc:creator>
<dc:creator>Amedeo Anselmi</dc:creator>
<dc:creator>Sylvain Beurtheret</dc:creator>
<dc:date>2024-07-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Time is relative, also when comparing transcatheter edge-to-edge repair to mitral valve surgery</dc:title>
<dc:identifier>pmid:38984394</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae383</dc:identifier>
</item>
<item>
<title>Investing in value-based primary care: a pathway to sustainable healthcare</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38984386/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240710141400&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 10:ehae404. doi: 10.1093/eurheartj/ehae404. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38984386/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240710141400&v=2.18.0.post9+e462414">38984386</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae404>10.1093/eurheartj/ehae404</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38984386</guid>
<pubDate>Wed, 10 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Kevin Cheng</dc:creator>
<dc:creator>Luigi Fontana</dc:creator>
<dc:date>2024-07-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Investing in value-based primary care: a pathway to sustainable healthcare</dc:title>
<dc:identifier>pmid:38984386</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae404</dc:identifier>
</item>
<item>
<title>Time matters when considering treatment for patients with mitral regurgitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38984374/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240710141400&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 10:ehae384. doi: 10.1093/eurheartj/ehae384. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38984374/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240710141400&v=2.18.0.post9+e462414">38984374</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae384>10.1093/eurheartj/ehae384</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38984374</guid>
<pubDate>Wed, 10 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Anne Bernard</dc:creator>
<dc:creator>Pierre Deharo</dc:creator>
<dc:creator>Laurent Fauchier</dc:creator>
<dc:date>2024-07-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Time matters when considering treatment for patients with mitral regurgitation</dc:title>
<dc:identifier>pmid:38984374</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae384</dc:identifier>
</item>
<item>
<title>Risk scores in congenital long QT syndrome: friend or foe?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38982981/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240710141400&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 10:ehae408. doi: 10.1093/eurheartj/ehae408. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38982981/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240710141400&v=2.18.0.post9+e462414">38982981</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae408>10.1093/eurheartj/ehae408</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38982981</guid>
<pubDate>Wed, 10 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Arthur A M Wilde</dc:creator>
<dc:creator>Christian van der Werf</dc:creator>
<dc:date>2024-07-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Risk scores in congenital long QT syndrome: friend or foe?</dc:title>
<dc:identifier>pmid:38982981</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae408</dc:identifier>
</item>
<item>
<title>Iron replacement in anthracycline-related cardiac dysfunction: fuel on the fire?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38982980/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240710141400&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 10:ehae411. doi: 10.1093/eurheartj/ehae411. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38982980/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240710141400&v=2.18.0.post9+e462414">38982980</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae411>10.1093/eurheartj/ehae411</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38982980</guid>
<pubDate>Wed, 10 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Muhummad Sohaib Nazir</dc:creator>
<dc:creator>Alexander R Lyon</dc:creator>
<dc:creator>Richard Southworth</dc:creator>
<dc:date>2024-07-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Iron replacement in anthracycline-related cardiac dysfunction: fuel on the fire?</dc:title>
<dc:identifier>pmid:38982980</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae411</dc:identifier>
</item>





























</channel>
</rss>